|1.||Sullivan, Daniel M: 4 articles (09/2009 - 02/2003)|
|2.||Marchion, Douglas C: 3 articles (09/2009 - 12/2005)|
|3.||Skladanowski, Andrzej: 2 articles (05/2010 - 08/2003)|
|4.||Inaba, Toshiya: 2 articles (10/2009 - 01/2003)|
|5.||Turner, Joel G: 2 articles (09/2009 - 12/2005)|
|6.||Barcos, Maurice: 2 articles (04/2008 - 09/2007)|
|7.||Sait, Sheila N J: 2 articles (04/2008 - 09/2007)|
|8.||Baer, Maria R: 2 articles (04/2008 - 09/2007)|
|9.||Daud, Adil I: 2 articles (12/2005 - 12/2005)|
|10.||Bicaku, Elona: 2 articles (12/2005 - 12/2005)|
09/01/1991 - "It can be interpreted from these results that topoisomerase II inhibitors could be effective in cancer patients due to the greater level of this enzyme in tumor cells than in normal tissues. "
10/01/2015 - "To develop novel selective topoisomerase II inhibitors, we designed and synthesized a series of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines and evaluated their topoisomerase inhibitory activity and cytotoxicity against three human cancer cell lines (DU145, HCT15, and T47D) and a normal cell line (MCF10A). "
12/01/2011 - "Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors."
08/01/2003 - "Catalytic topoisomerase II inhibitors in cancer therapy."
02/01/2003 - "Tumor p53 status and response to topoisomerase II inhibitors."
01/01/2011 - "Topoisomerase II inhibitors induce mainly acute leukemias which invariably correlate with dysregulation of the MLL gene. "
07/01/2009 - "A balanced translocation involving 11q23 (MLL gene) could be observed in therapy related leukemia (TRL) patients generally treated with topoisomerase II inhibitors. "
10/01/2007 - "Balanced chromosome rearrangements are the hallmark of therapy-related leukemia that develops in patients treated with topoisomerase II inhibitors. "
09/08/2006 - "Felix, Leukemias related to treatment with DNA topoisomerase II inhibitors, Med. Pediatr. "
12/01/2005 - "Exposure to topoisomerase II inhibitors is linked to the generation of leukemia involving translocations of the MLL gene, normally restricted to an 8.3 kbp tract, the breakpoint cluster region (BCR). "
|3.||Breast Neoplasms (Breast Cancer)
01/01/2009 - "Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells."
01/01/2000 - "Influence of topoisomerase II inhibitors and ionizing radiation on growth arrest and cell death pathways in the breast tumor cell."
04/15/1998 - "Previous work from this laboratory has demonstrated an association between the suppression of c-myc expression and the antiproliferative activity of both topoisomerase II inhibitors and ionizing radiation in MCF-7 breast tumor cells. "
01/01/1998 - "The results of these studies extend previous results from this laboratory indicating an association between suppression of c-myc expression, inhibition of DNA synthesis and growth arrest by topoisomerase II inhibitors, as well as the lack of induction of apoptotic cell death by topoisomerase II inhibitors in MCF-7 breast tumor cells."
01/01/2010 - "Alkylating agents and topoisomerase II inhibitors, fundamental to the treatment of breast cancer, are the most likely contributors to this increase in risk. "
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2014 - "Sequence-dependent improved efficacy of topoisomerase I followed by topoisomerase 2 inhibitors was assessed in a randomized phase II study in extensive-stage small-cell lung cancer (SCLC). "
05/01/1993 - "[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]."
02/15/1990 - "Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors."
02/15/1990 - "In an attempt to clarify the role of drug-induced protein-associated DNA breaks (i.e., DNA topoisomerase II-mediated DNA cleavage) in the cytotoxic activity of doxorubicin and etoposide, their cellular effects were compared in 2 human small-cell lung cancer (SCLC) lines, characterized by differential sensitivity to DNA topoisomerase II inhibitors. "
02/01/2011 - "Based on preclinical activity of voreloxin in chemoresistant tumors, early phase I clinical activity, and a mechanism of action similar to other topoisomerase II inhibitors such as the anthracyclines and etoposide, this phase II trial was undertaken as second-line treatment of small cell lung cancer (SCLC). "
02/01/2007 - "The aim of this study was to compare the effect of several commercially available topoisomerase II inhibitors on the proliferation of retinal pigment epithelium (RPE) cells in vitro and to test the toxicity and efficacy of the inhibitor against experimental proliferative vitreoretinopathy (PVR). "
02/01/2007 - "Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy."
|1.||Etoposide (VP 16)
|2.||Type I DNA Topoisomerases (Topoisomerase I)
|4.||Type II DNA Topoisomerases (Topoisomerase II)
|6.||Messenger RNA (mRNA)
|9.||NF-kappa B (NF-kB)
|1.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)